Pharming To Present At UBS Global Life Sciences Conference

Leiden, The Netherlands, September 21, 2006. Biotech company Pharming Group NV (“Pharming”) (Euronext: PHARM) (PHARM.AS) announced today that Dr. Francis Pinto, Chief Executive Officer of Pharming will present at the UBS Global Life Sciences Conference (September 25-28, 2006) in New York.

Dr. Pinto will present on Monday, September 25 at 2:00 pm Eastern Time. For further information on the UBS Global Life Sciences Conference, please visit www.ibb.ubs.com.

Background on Pharming Group NV
Pharming Group NV is developing innovative protein products for the treatment of genetic disorders, specialty products for surgical indications, intermediates for various applications and food products. Pharming has two products in late stage development - Rhucin® (recombinant human C1 inhibitor) for hereditary angioedema (under review by EMEA) and human lactoferrin for use in functional foods (GRAS notification under review by US FDA). The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, as well as technology and processes for the purification and formulation of these products. Additional information is available on the Pharming website, http://www.pharming.com.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.

Contact Information

Samir Singh

Pharming Group NV

Contact via E-mail